Dauricine exhibits anti-inflammatory property against acute ulcerative colitis via the regulation of NF-κB pathway

Cell Biochem Funct. 2023 Aug;41(6):713-721. doi: 10.1002/cbf.3826. Epub 2023 Jul 20.

Abstract

We aim to investigate the therapeutic effect of dauricine on ulcerative colitis (UC). Our results indicated that dauricine attenuated the reduction of colonic length, weight loss, disease activity index, colonic tissue damage, and inflammatory cytokine levels in dextran sulfate sodium mice. In addition, dauricine reduced lipopolysaccharide-induced inflammation in HT-29 cells. Mechanically, dauricine docked with p65, a member of nuclear transcription factor kappaB (NF-κB) family, through which reduced the inflammatory cytokine release from HT-29 cells. Together, the above results inferred that dauricine had therapeutic effect for UC by suppressing NF-κB pathway, which provided a promising mean for UC treatment.

Keywords: NF-κB pathway; acute ulcerative colitis; dauricine; inflammation.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Colitis, Ulcerative* / chemically induced
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / metabolism
  • Colon / metabolism
  • Cytokines / metabolism
  • Dextran Sulfate / adverse effects
  • Dextran Sulfate / metabolism
  • Disease Models, Animal
  • Mice
  • NF-kappa B* / metabolism
  • Signal Transduction

Substances

  • NF-kappa B
  • dauricine
  • Anti-Inflammatory Agents
  • Cytokines
  • Dextran Sulfate